Reece et al report that single-agent bortezomib resulted in hematologic responses in two-thirds of patients with relapsed Light chain (AL) amyloidosis, including complete responses in one-third, while more than 75% of patients had response duration of more than or equal to 1 year.[1][1]
![Figure][2
Efstathios Kastritis, Ashutosh Wechalekar, Meletios A Dimopoulos, Giampaolo Merlini, Philip N. Hawkins, Vittorio Perfetti, Julian D. Gillmore, Giovanni Palladini
Discussion(0)
No comments yet. Be the first to comment.